Bio-Techne Corp
TECH65.700USD
+1.120+1.73%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
10.23BMarket Cap
131.56P/E TTM
More Details of Bio-Techne Corp Company
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
Bio-Techne Corp Info
Ticker SymbolTECH
Company nameBio-Techne Corp
IPO dateFeb 09, 1989
CEOKelderman (Kim)
Number of employees3100
Security typeOrdinary Share
Fiscal year-endFeb 09
Address614 Mckinley Pl N E
CityMINNEAPOLIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code55413
Phone16123798854
Websitehttps://www.bio-techne.com/
Ticker SymbolTECH
IPO dateFeb 09, 1989
CEOKelderman (Kim)
Company Executives of Bio-Techne Corp
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+1640.00%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-2303.00%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+1640.00%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+1640.00%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+1640.00%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+1640.00%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
4.38K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
3.78K
+1640.00%
Mr. James T. (Jim) Hippel
Mr. James T. (Jim) Hippel
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
--
--
Mr. David Clair
Mr. David Clair
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+1640.00%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-2303.00%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+1640.00%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+1640.00%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+1640.00%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+1640.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumables
231.60M
80.82%
Service
27.48M
9.59%
Instruments
21.83M
7.62%
Royalty
5.65M
1.97%
By RegionUSD
Name
Revenue
Proportion
United States
155.24M
54.17%
EMEA, excluding U.K
65.13M
22.73%
Greater China
24.79M
8.65%
APAC, excluding Greater China
19.15M
6.68%
United Kingdom
13.21M
4.61%
Rest of World
9.05M
3.16%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
231.60M
80.82%
Service
27.48M
9.59%
Instruments
21.83M
7.62%
Royalty
5.65M
1.97%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Other
72.73%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Other
72.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
58.57%
Investment Advisor/Hedge Fund
34.00%
Hedge Fund
8.06%
Bank and Trust
2.18%
Research Firm
1.96%
Pension Fund
1.35%
Sovereign Wealth Fund
1.24%
Individual Investor
0.28%
Insurance Company
0.24%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1201
167.79M
107.68%
+389.22K
2025Q3
1198
161.18M
103.53%
-7.34M
2025Q2
1209
165.25M
105.41%
-730.33K
2025Q1
1245
168.10M
107.22%
+1.54M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
17.89M
11.48%
-504.17K
-2.74%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.79M
5.64%
-7.47K
-0.08%
Sep 30, 2025
State Street Investment Management (US)
5.75M
3.69%
-105.19K
-1.80%
Sep 30, 2025
Wellington Management Company, LLP
5.12M
3.28%
+3.98M
+349.84%
Sep 30, 2025
Atlanta Capital Management Company, L.L.C.
4.94M
3.17%
+646.77K
+15.06%
Sep 30, 2025
Geode Capital Management, L.L.C.
4.93M
3.16%
+864.67K
+21.28%
Sep 30, 2025
Invesco Capital Management LLC
3.51M
2.26%
+275.06K
+8.49%
Sep 30, 2025
Neuberger Berman, LLC
3.31M
2.12%
+807.15K
+32.29%
Sep 30, 2025
T. Rowe Price Associates, Inc.
3.12M
2%
-5.50M
-63.78%
Sep 30, 2025
Maverick Capital, Ltd.
3.01M
1.93%
+3.01M
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Genomics & Biotechnology ETF
4.29%
Invesco Biotechnology & Genome ETF
2.92%
Invesco S&P 500 Equal Weight Health Care ETF
2%
Neuberger Berman Small-Mid Cap ETF
1.78%
VanEck Biotech ETF
1.73%
Hilton Small-MidCap Opportunity ETF
1.7%
iShares Health Innovation Active ETF
1.68%
American Century Mid Cap Growth Impact ETF
1.47%
Thrivent Small-Mid Cap ESG ETF
1.34%
Invesco S&P 500 High Beta ETF
1.06%
View more
Global X Genomics & Biotechnology ETF
Proportion4.29%
Invesco Biotechnology & Genome ETF
Proportion2.92%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion2%
Neuberger Berman Small-Mid Cap ETF
Proportion1.78%
VanEck Biotech ETF
Proportion1.73%
Hilton Small-MidCap Opportunity ETF
Proportion1.7%
iShares Health Innovation Active ETF
Proportion1.68%
American Century Mid Cap Growth Impact ETF
Proportion1.47%
Thrivent Small-Mid Cap ESG ETF
Proportion1.34%
Invesco S&P 500 High Beta ETF
Proportion1.06%
Dividend
A total of
250.90M
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Nov 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 28, 2025 going ex on Nov 17, 2025
Nov 17, 2025
Nov 28, 2025
Nov 17, 2025
Aug 06, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 29, 2025 going ex on Aug 18, 2025
Aug 18, 2025
Aug 29, 2025
Aug 18, 2025
May 07, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 30, 2025 going ex on May 19, 2025
May 19, 2025
May 30, 2025
May 19, 2025
Feb 05, 2025
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
View more
Stock Split
Date
Type
Ratio
Nov 01, 2022
Split
1→4
Date
Type
Ratio
Nov 01, 2022
Split
1→4
FAQs
Who are the top five shareholders of Bio-Techne Corp?
The top five shareholders of Bio-Techne Corp are:
The Vanguard Group, Inc. holds 17.89M shares, accounting for 11.48% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.79M shares, accounting for 5.64% of the total shares.
State Street Investment Management (US) holds 5.75M shares, accounting for 3.69% of the total shares.
Wellington Management Company, LLP holds 5.12M shares, accounting for 3.28% of the total shares.
Atlanta Capital Management Company, L.L.C. holds 4.94M shares, accounting for 3.17% of the total shares.
The Vanguard Group, Inc. holds 17.89M shares, accounting for 11.48% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.79M shares, accounting for 5.64% of the total shares.
State Street Investment Management (US) holds 5.75M shares, accounting for 3.69% of the total shares.
Wellington Management Company, LLP holds 5.12M shares, accounting for 3.28% of the total shares.
Atlanta Capital Management Company, L.L.C. holds 4.94M shares, accounting for 3.17% of the total shares.
What are the top three shareholder types of Bio-Techne Corp?
The top three shareholder types of Bio-Techne Corp are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Bio-Techne Corp (TECH)?
As of 2025Q4, 1201 institutions hold shares of Bio-Techne Corp, with a combined market value of approximately 167.79M, accounting for 107.68% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 4.16%.
What is the biggest source of revenue for Bio-Techne Corp?
In FY2026Q1, the Consumables business generated the highest revenue for Bio-Techne Corp, amounting to 231.60M and accounting for 80.82% of total revenue.
